Also, we used an immunohistochemical (IHC) assay to analyze the expression of MYH9 in clinical tissue samples of lung cancer and found that it can be used as an independent factor in evaluating the prognosis of patients with NSCLC. This evidence concerns the gene MYH9 and lung carcinoma.